1600-6143/asset/olbannerleft.gif?v=1&s=c46a3f174bfd9c6eb548cc809401524372c32e90)
1600-6143/asset/olbannerright.gif?v=1&s=9fc9790fa8ad5ef85aeaf408bf0d3d969d2fc012)
Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio-Pulmonary By-Pass
Article first published online: 31 AUG 2007
DOI: 10.1111/j.1600-6143.2007.01945.x
Additional Information
How to Cite
Corno, V., Dezza, M. C., Lucianetti, A., Codazzi, D., Carrara, B., Pinelli, D., Parigi, P. C., Guizzetti, M., Strazzabosco, M., Melzi, M. L., Gaffuri, G., Sonzogni, V., Rossi, A., Fagiuoli, S. and Colledan, M. (2007), Combined Double Lung–Liver Transplantation for Cystic Fibrosis Without Cardio-Pulmonary By-Pass. American Journal of Transplantation, 7: 2433–2438. doi: 10.1111/j.1600-6143.2007.01945.x
Publication History
- Issue published online: 31 AUG 2007
- Article first published online: 31 AUG 2007
- Received 21 February 2007, revised 05 July 2007 and accepted for publication 11 July 2007
- Abstract
- Article
- References
- Cited By
Keywords:
- Cystic fibrosis;
- liver transplantation;
- lung transplantation
Combined sequential bilateral single lung-liver transplantation is a treatment option for patient with cystic fibrosis who would not be expected to survive transplantation of either organ alone, and can be safely performed without cardiopulmonary by-pass.
Sequential bilateral single lung-liver transplantation (SBSL-LTx) is a therapeutic option for patients with end stage lung and liver disease (ESLLD) due to cystic fibrosis (CF). A few cases have been reported, all of them were performed with the use of cardio-pulmonary by-pass (CPB). We performed SBSL-LTx in three young men affected by CF. All the recipients had respiratory failure and portal hypertension with hypersplenism. Along with lung transplants, two patients received a whole liver graft and one an extended right graft from an in situ split liver. During transplantation neither CPB nor veno-venous by-pass (VVB) were employed. Immunosuppression was based on basiliximab, tacrolimus, steroids and azathioprine. The three recipients are alive with a median follow-up of 670 days (range 244–1533). Combined SBSL-LTx is a complex but effective procedure for the treatment of ESLLD due to CF, not necessarily requiring the use of CPB or VVB.